This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer
a)Patients with histologically confirmed HER2-expressing recurrent or metastatic cervical cancer who have failed at least 1 line of standard platinum-containing therapy ; b) Not suitable for surgery or radiotherapy;
Voluntarily agreed to participate in the study and signed an informed consent form.
Female, age ≥ 18 years
Expected survival ≥ 12 weeks
Have central nervous system metastases and/or carcinomatous meningitis.
Received anti-tumour therapy or participated in another clinical study treatment within 4 weeks prior to the start of study treatment.
Toxicity due to previous antineoplastic therapy has not recovered to NCI-CTCAE (version 5.0) grade 0-1.
Major surgery with incomplete recovery within 4 weeks prior to start of study dosing.